In silico analysis to explore the therapeutic potential of propolis-derived small molecules as matriptase inhibitors to suppress breast cancer growth and metastasis
PLOS One · 2025
DOI: 10.1371/journal.pone.0321687 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Muhammad Bilal Azmi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Computational Biochemistry Research Laboratory, Department of Biochemistry, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms, Propolis, Serine Endopeptidases, Antineoplastic Agents. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer is a major cause of death in women, and various drug therapies are used for its treatment. However, current therapies have many side effects and limitations. Propolis, a resinous product of bee hives, possesses a variety of biological activities, including anticancer and chemo-protective properties. The present study aimed to investigate the potential suitability of propolis-derived compounds to inhibit matriptase (MT-SP1), a potential protein target for breast cancer treatment, through comprehensive computational analysis. The MT-SP1 protein structure (PDB ID: 1EAX) was retrieved, energy-minimized, and validated. Five propolis-derived compounds with the highest binding energies to MT-SP1 were selected after virtual screening. Molecular docking of these selected ligands revealed binding energies ranging from -8.4 to -9.1 kcal/mol. Stable complex formation was validated by an additional 250 ns of molecular dynamics simulations. The HOMO-LUMO and DFT characteristics provided further evidence of the chemical reactivity and stability of these five ligands at the MT-SP1 active site. Screening of compounds for drug-likeness, pharmacokinetics (ADMET profiles), and toxicity identified two promising small molecules (PubChem IDs of ligands 72307 and 129827386) as potential drug candidates for inhibiting MT-SP1. However, experimental validation through in vitro or in vivo studies is necessary to confirm these computational findings and explore their therapeutic potential for breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Computational Biochemistry Research Laboratory, Department of Biochemistry, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
- Children's Hospital Affiliated to Shandong University, Jinan, China.
- Jinan Children's Hospital, Jinan, China.
- Department of Computational Biology, School of Life Sciences, Fudan University, Shanghai, China.
- Department of Biochemistry, Medicine Program, Batterjee Medical College, Jeddah, Saudi Arabia.
- Department of Biochemistry, University of Karachi, Karachi, Pakistan.
ORCID-Profile: Muhammad Bilal Azmi, Han Yu, Uzma Asif
Zitieren
APA
Azmi, M. B., Yu, H., Sohail, A., Asif, U., Ahmed, S. D. H., Qureshi, S. A., & Abdalla, M. (2025). In silico analysis to explore the therapeutic potential of propolis-derived small molecules as matriptase inhibitors to suppress breast cancer growth and metastasis. PLOS One. https://doi.org/10.1371/journal.pone.0321687
Vancouver
Azmi MB, Yu H, Sohail A, Asif U, Ahmed SDH, Qureshi SA, et al. In silico analysis to explore the therapeutic potential of propolis-derived small molecules as matriptase inhibitors to suppress breast cancer growth and metastasis. PLOS One. 2025. doi:10.1371/journal.pone.0321687
BibTeX
@article{Azmi2025,
author = {Azmi, Muhammad Bilal and Yu, Han and Sohail, Arisha and Asif, Uzma and Ahmed, Syed Danish Haseen and Qureshi, Shamim Akhtar and Abdalla, Mohnad},
title = {In silico analysis to explore the therapeutic potential of propolis-derived small molecules as matriptase inhibitors to suppress breast cancer growth and metastasis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321687}
}
EUVIMED